HUTCHMED (China) (HUTCHMED (China)) LT-Debt-to-Total-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HUTCHMED (China)'s long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.04.

HUTCHMED (China)'s long-term debt to total assets ratio increased from Dec. 2022 (0.02) to Dec. 2023 (0.04). It may suggest that HUTCHMED (China) is progressively becoming more dependent on debt to grow their business.

HUTCHMED (China) LT-Debt-to-Total-Asset Historical Data

The historical data trend for HUTCHMED (China)'s LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) LT-Debt-to-Total-Asset Chart

HUTCHMED (China) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.05

0.01

0.02

0.04

HUTCHMED (China) Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	-	0.02	0.03	0.04

HUTCHMED (China) LT-Debt-to-Total-Asset Calculation

HUTCHMED (China)'s Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	51.049	/	1279.773
	=	0.04

HUTCHMED (China)'s Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	51.049	/	1279.773
	=	0.04

HUTCHMED (China) (NAS:HCM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

HUTCHMED (China) LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.